Display Settings:

Items per page
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 8

1.
Figure 8

Figure 8. Spots of lymphohistiocytic inflammation around terminal and respiratory bronchioles. From: Sendai virus-based RSV vaccine protects African green monkeys from RSV infection.

Upon histopathology examinations, there were minimal to mild spots of lymphohistiocytic inflammation around terminal and respiratory bronchioles in all animals. Illustrations of spots in animals that received A. PBS, B. SeV, and C. SeVRSV are shown.

Bart G. Jones, et al. Vaccine. ;30(5):959-968.
2.
Figure 1

Figure 1. Experimental design for SeVRSV vaccine analysis. From: Sendai virus-based RSV vaccine protects African green monkeys from RSV infection.

Animals were grouped to receive PBS, SeV or SEVRSV as vaccines by the i.n. and i.t. routes, and were later challenged with RSV (Panel A). Time points for collections, vaccinations and challenges are diagrammed in Panel B.

Bart G. Jones, et al. Vaccine. ;30(5):959-968.
3.
Figure 7

Figure 7. Protection against RSV challenge in the LRT. From: Sendai virus-based RSV vaccine protects African green monkeys from RSV infection.

Animals were sampled after challenge on days 3,5,7, and 10 for RSV in the BAL. Results for PBS and SeV control animals are shown in left panels as blue and red lines, respectively. Results for SeVRSV-primed animals are shown in right panels as green lines. ND=Not Detected.

Bart G. Jones, et al. Vaccine. ;30(5):959-968.
4.
Figure 4

Figure 4. Serum antibodies in primed animals. From: Sendai virus-based RSV vaccine protects African green monkeys from RSV infection.

Animals were sampled prior to vaccination and on days 10, 14 and 25 for serum antibodies. Panels A, B, and C show responses to SeV by animals vaccinated with PBS, SeV and SeVRSV, respectively. Panels D, E, and F show responses to RSV by animals vaccinated with PBS, SeV and SeVRSV, respectively.

Bart G. Jones, et al. Vaccine. ;30(5):959-968.
5.
Figure 6

Figure 6. Protection against RSV challenge in the URT. From: Sendai virus-based RSV vaccine protects African green monkeys from RSV infection.

Animals were sampled after challenge on days 3,5,7, and 10 for RSV in the NW (A,B) and TS (C,D). Results for PBS and SeV control animals are shown in left panels as blue and red lines, respectively. Results for SeVRSV-primed animals are shown in right panels as green lines. ND=Not Detected.

Bart G. Jones, et al. Vaccine. ;30(5):959-968.
6.
Figure 5

Figure 5. Antibodies in the nasal wash of primed animals. From: Sendai virus-based RSV vaccine protects African green monkeys from RSV infection.

Animals were sampled prior to vaccination and on days 10, 14 and 25 for nasal wash antibodies. Panels A, B, and C show responses to SeV by animals vaccinated with PBS, SeV and SeVRSV, respectively. Panels D, E, and F show responses to RSV by animals vaccinated with PBS, SeV and SeVRSV, respectively.

Bart G. Jones, et al. Vaccine. ;30(5):959-968.
7.
Figure 3

Figure 3. SeVRSV presence in the LRT. From: Sendai virus-based RSV vaccine protects African green monkeys from RSV infection.

Animals were sampled on days 3,5,7,10 and 14 for vaccine virus in the BAL. Results from individual animals are shown in Panel A. Averages for BAL are shown in Panel B. Results for animals that received PBS, SeV or SeVRSV are indicated by blue, red and green lines, respectively. The asterisk and solid line in Panel B indicate the mean peak viral titer in BAL samples for a PIV-3-based RSV vaccine described in previous literature [22]. ND=Not Detected.

Bart G. Jones, et al. Vaccine. ;30(5):959-968.
8.
Figure 2

Figure 2. SeVRSV presence in the URT. From: Sendai virus-based RSV vaccine protects African green monkeys from RSV infection.

Animals were sampled on days 3,5,7,10 and 14 for vaccine virus in the NW or TS. NW results from individual animals are shown in panel A. Averages are in Panel B. Results for animals that received PBS, SeV or SeVRSV are indicated by blue, red and green lines, respectively. The asterisk and solid line in Panel B indicate the mean peak viral titer in nasopharyngeal swab samples for a PIV-3-based RSV vaccine described in previous literature [22]. TS results from individual animals are shown in Panel C. Averages for TS are shown in Panel D. ND=Not Detected.

Bart G. Jones, et al. Vaccine. ;30(5):959-968.

Display Settings:

Items per page

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk